Gray baby syndrome
|Gray baby syndrome|
|Other names||Grey baby syndrome, Gray syndrome, Grey syndrome|
|Specialty||Pediatrics, Infectious Disease, Toxicology|
|Symptoms||Vomiting, Greenish Diarrhea, Abdominal Distension, Hypothermia, Pallid Cyanosis, Irregular Respiration, Circulatory Collapse|
|Complications||Bleeding, Hepatic failure, Anemia, Kernicterus, Death|
|Causes||Accumulation of chloramphenicol|
|Diagnostic method||proper history taking, monitoring blood level of the drug|
Gray baby syndrome (also termed Gray or Grey syndrome) is a rare but serious, even fatal, side effect that occurs in newborn infants (especially premature babies) following the accumulation of antibiotic chloramphenicol. Chloramphenicol is a broad-spectrum antibiotic that has been used to treat a variety of bacteria infections like Streptococcus pneumoniae as well as typhoid fever, meningococcal sepsis, cholera, and eye infections. Chloramphenicol works by binding to ribosomal subunits which blocks transfer ribonucleic acid and prevents the synthesis of bacterial proteins. Chloramphenicol has also been used to treat neonates born before 37 weeks of the gestational period for prophylaxis purposes. In 1958, newborns born prematurely due to rupture of the amniotic sac were given chloramphenicol to prevent possible infections, and it was noticed that these newborns had a higher mortality rate compared with those who were not treated with the antibiotic. Over the years, chloramphenicol has been used less in clinical practices due to the risks of toxicity not only to neonates, but also to adults due to the risk of aplastic anemia. Chloramphenicol is now reserved to treat certain severe bacteria infections that were not successfully treated with other antibiotic medications. Signs and symptoms are summarized in the WHO Model Formulary for Children 2010 under the rare adverse effect section of chloramphenicol.
Signs and symptoms
Since the syndrome is due to the accumulation of chloramphenicol, the signs and symptoms are dose related. According to Kasten's review published in the Mayo Clinic Proceedings, a serum concentration of more than 50 μg/mL is a warning sign, while Hammett-Stabler and John states that the common therapeutics peak level is 10-20 μg/mL and is expected to achieve after 0.5-1.5 hours of intravenous administration in their review of antimicrobial dugs. The common onset of signs and symptoms are 2 to 9 days after the initiation of the medication, which allows the serum concentration to build up to reach the toxic concentration above. Common signs and symptoms include loss of appetite, fussiness, vomiting, ashen gray color of the skin, hypotension (low blood pressure), cyanosis (blue discoloration of lips and skin), hypothermia, cardiovascular collapse, hypotonia (muscle stiffness), abdominal distension, irregular respiration, and increased blood lactate.
Two pathophysiologic mechanisms are thought to play a role in the development of gray baby syndrome after exposure to chloramphenicol. This condition is due to a lack of glucuronidation reactions occurring in the baby (phase II hepatic metabolism), thus leading to an accumulation of toxic chloramphenicol metabolites:
- Metabolism: The UDP-glucuronyl transferase enzyme system in infants, especially premature infants, is not fully developed and incapable of metabolizing the excessive drug load needed to excrete chloramphenicol.
- Elimination: Insufficient renal excretion of the unconjugated drug.
Insufficient metabolism and excretion of chloramphenicol leads to increased blood concentrations of the drug, causing blockade of the electron transport of the liver, myocardium, and skeletal muscles. Since the electron transport is an essential part of cellular respiration, its blockade can result in cell damage. In addition, the presence of chloramphenicol weakens the binding of bilirubin and albumin, so increased levels of the drug can lead to high levels of free bilirubin in the blood, resulting in brain damage or kernicterus.If left untreated, possible bleeding, renal (kidney) and/or hepatic (liver) failure, anemia, infection, confusion, weakness, blurred vision, or eventually death are expected. Additionally, chloramphenicol is significantly insoluble due to an absence of acidic and basic groups in its molecular compound. As a result, larger amounts of the medication are required to achieve the desired therapeutic effect. High volumes of a medication that can cause various toxicities is another avenue how chloramphenicol can potentially lead to grey baby syndrome.
Gray baby syndrome should be suspected in a new born with abdominal distension, progressive pallid cyanosis, irregular respirations, and refusal to breastfeed. The cause of gray baby syndrome can come from the direct use of intravenous or oral chloramphenicol in neonates. Direct chronological relation between the use of the medication and signs and symptoms of the syndrome should be found in the previous medical history. In terms of the possible route of chloramphenicol, gray baby syndrome may not come from the mother's use of chloramphenicol during pregnancy or breastfeeding. According to the Drug and Lactation database (LactMed), it states that "milk concentrations are not sufficient to induce gray baby syndrome". It is also reported that the syndrome may not develop in infants when their mothers use the medication in their late period of pregnancy. According to the Oxford Review, chloramphenicol given to mothers during their pregnancy did not result in gray baby syndrome, but was caused by infants receiving supra-therapeutic doses of chloramphenicol after birth. The presentation of symptoms can depend on the level of exposure of the drug to the baby, given its dose-related nature. A broad diagnosis is usually needed for babies who present with cyanosis. To support the diagnosis, blood work should be done to determine the level of serum chloramphenicol, and to further evaluate chloramphenicol toxicity, a complete blood panel including levels of serum ketones, glucose (due to the risk of hypoglycemia), metabolic panel should be completed to help determine if an infant has the syndrome. Other tools used to help with diagnosis include CT scans, ultrasound, and electrocardiogram.
Since the syndrome is a side effect of chloramphenicol, the prevention is primarily related to the proper use of the medication. The WHO Model Formulary for Children 2010 recommends to reserve chloramphenicol for life-threatening infections. As well as using chloramphenicol only when necessary, it should also be used in short periods of time to also prevent the potential for toxicity. In particular, this medication should not be prescribed especially in neonates less than one week old due to the significant risk of toxicity. Preterm infants especially should not be administered chloramphenicol. Gray baby syndrome has been noted to be dose-dependent as it typically occurs in neonates who have received a daily dose greater than 200 milligrams.
When chloramphenicol is necessary, the condition can be prevented by using chloramphenicol at the recommended doses and monitoring blood levels, or alternatively, third generation cephalosporins can be effectively substituted for the drug, without the associated toxicity. Also, repeated course of administration and prolonged treatment should be avoided as much as possible. In terms of hepatic development in neonates, it take only weeks from birth for them to develop their UDPGT expression and function to be at an adult-like level, while the function is only about 1% in the late pregnancy, even right before birth-giving. According to MSD Manuals, chloramphenicol should not be given to neonates with younger than 1 month of age with more than a dose of 25 mg/kg/day to start with. The serum concentration of the medication should be monitored to titrate to a therapeutic level and to prevent toxicity. Medication reconciliation of other medications that neonates may be taking that can decrease blood cell count should be monitored because of this medication's ability to suppress bone marrow activity. Rifampicin and trimethoprim are examples of medications with bone marrow suppression abilities and are contraindicated for concomitant use with chloramphenicol. In regards to bone marrow suppression, chloramphenicol has two major etiological manifestations. The first mechanism of bone marrow suppression affects the formation of blood cells such as erythrocytes, and this can be reversible since it is an early sign up toxicity. The second form of bone marrow suppression is bone marrow aplasia, which is associated with being late into toxicity and cannot be reversed in some cases. Chloramphenicol is contraindicated in persons who are breastfeeding due to the risk of toxic effects in the baby, but if maternal use of chloramphenicol cannot be avoided, close monitoring of the baby's symptoms such as feeding difficulties, and blood work is recommended.
Chloramphenicol therapy should be stopped immediately if objective or subjective signs of gray baby syndrome are suspected since gray baby syndrome can be fatal for the infant if it is not diagnosed early on as it can lead to anemia, shock, and end-organ damage. After discontinuing the antibiotic, the side effects caused by the toxicity should be treated. This includes treating hypoglycemia to help prevent hemodynamic instability, as well as increasing the temperature of the infant if they have developed hypothermia. Since symptoms of gray baby syndrome are correlated with elevated serum chloramphenicol concentrations, exchange transfusion may be required to remove the drug, charcoal column hemoperfusion is a type of transfusion that has shown significant effects but is associated with numerous side effects. The associated side effects isn't the only reason why this method of treatment is not a first line therapy. According to the American Journal of Kidney Disease, elevated cartridge prices and viable lifespan of the product are deterring factors to consider. Phenobarbital and theophylline are two drugs in particular that have shown significant efficacy with charcoal hemoperfusion, aside from its most significant indication for chronic aluminum toxicity in people with end-stage renal disease (ESRD) traditionally. Sometimes, phenobarbital is used to induce UDP-glucuronyl transferase enzyme function. For hemodynamically unstable neonates, supportive care measures such as resuscitation, oxygenation, and treatment for hypothermia are common practices when cessation of chloramphenicol alone is insufficient. With sepsis being a complication of severe gray baby syndrome, usage of broad-spectrum antibiotics such as vancomycin, for example, is a recommended treatment option. Third generation antibiotics have also proven efficacy in treating gray baby-induced sepsis.
- McIntyre J, Choonara I (2004). "Drug toxicity in the neonate". Biology of the Neonate. 86 (4): 218–21. doi:10.1159/000079656. PMID 15249753. S2CID 29906856.
- Deveci A, Coban AY (September 2014). "Optimum management of Citrobacter koseri infection". Expert Review of Anti-Infective Therapy. 12 (9): 1137–42. doi:10.1586/14787210.2014.944505. PMID 25088467.
- "Chloramphenicol", LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID 31643435, retrieved 2021-08-02
- Oong GC, Tadi P (2021). "Chloramphenicol". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32310426. Retrieved 2021-08-02.
- Vázquez-Laslop N, Mankin AS (September 2018). "Context-Specific Action of Ribosomal Antibiotics". Annual Review of Microbiology. 72 (1): 185–207. doi:10.1146/annurev-micro-090817-062329. PMID 29906204.
- Cummings ED, Kong EL, Edens MA (2021). "Gray Baby Syndrome". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 28846297. Retrieved 2021-07-30.
- Powell DA, Nahata MC (April 1982). "Chloramphenicol: new perspectives on an old drug". Drug Intelligence & Clinical Pharmacy. 16 (4): 295–300. doi:10.1177/106002808201600404. PMID 7040026.
- Ingebrigtsen SG, Didriksen A, Johannessen M, Škalko-Basnet N, Holsæter AM (June 2017). "Old drug, new wrapping - A possible comeback for chloramphenicol?". International Journal of Pharmaceutics. 526 (1–2): 538–546. doi:10.1016/j.ijpharm.2017.05.025. hdl:10037/12466. PMID 28506801.
- Beninger P (December 2018). "Pharmacovigilance: An Overview". Clinical Therapeutics. 40 (12): 1991–2004. doi:10.1016/j.clinthera.2018.07.012. PMID 30126707.
- WHO model formulary for children 2010. World Health Organization. 2010. ISBN 978-92-4-159932-0.
- Kasten MJ (1999). "Clindamycin, metronidazole, and chloramphenicol". Mayo Clinic Proceedings. 74 (8): 825–33. doi:10.4065/74.8.825. PMID 10473362.
- Hammett-Stabler CA, Johns T (1998). "Laboratory guidelines for monitoring of antimicrobial drugs". Clinical Chemistry. 44 (5): 1129–40. doi:10.1093/clinchem/44.5.1129. PMID 9590397.
- Chambers HF (2005). "Chapter 46. Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents". In Brunton EL, Lazo JS, Parker K (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. pp. 1173–1202. ISBN 978-0-07-142280-2.
- Meissner HC, Smith AL (1979). "The current status of chloramphenicol". Pediatrics. 64 (3): 348–56. PMID 384354.
- "Chloramphenicol". Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US). 2006. PMID 30000554. Retrieved 2021-07-30.
- Yu PA, Tran EL, Parker CM, Kim HJ, Yee EL, Smith PW, et al. (2020). "Safety of Antimicrobials During Pregnancy: A Systematic Review of Antimicrobials Considered for Treatment and Postexposure Prophylaxis of Plague". Clinical Infectious Diseases. 70 (70 Suppl 1): S37–S50. doi:10.1093/cid/ciz1231. PMID 32435799.
- Feder HM (1986). "Chloramphenicol: what we have learned in the last decade". Southern Medical Journal. 79 (9): 1129–34. doi:10.1097/00007611-198609000-00022. PMID 3529436.
- Mulhall A, de Louvois J, Hurley R (1983). "Chloramphenicol toxicity in neonates: its incidence and prevention". British Medical Journal. 287 (6403): 1424–7. doi:10.1136/bmj.287.6403.1424. PMC 1549666. PMID 6416440.
- Forster J, Hufschmidt C, Niederhoff H, Künzer W (1985). "[Need for the determination of chloramphenicol levels in the treatment of bacterial-purulent meningitis with chloramphenicol succinate in infants and small children]". Monatsschrift Kinderheilkunde. 133 (4): 209–13. PMID 4000136.
- Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, Hoff DS (2020). "Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List". The Journal of Pediatric Pharmacology and Therapeutics. 25 (3): 175–191. doi:10.5863/1551-6776-25.3.175. PMC 7134587. PMID 32265601.
- Aggarwal R, Sarkar N, Deorari AK, Paul VK (2001). "Sepsis in the newborn". Indian Journal of Pediatrics. 68 (12): 1143–7. doi:10.1007/BF02722932. PMID 11838570. S2CID 20554642.
- Grijalva J, Vakili K (2013). "Neonatal liver physiology". Seminars in Pediatric Surgery. 22 (4): 185–9. doi:10.1053/j.sempedsurg.2013.10.006. PMID 24331092.
- Werth, Brian J (2020). "Chloramphenicol". MSD Manual Professional Edition. Retrieved 2021-07-30.
- Padberg S (2016). "Chloramphenicol". In Schaefer C, Peters P, Miller RK (eds.). Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (Sixteenth ed.). Amsterdam. pp. 229–236. doi:10.1016/B978-0-444-53717-1.00472-8. ISBN 978-0-444-53716-4.
- Padberg S (2015). "Anti-infectives". Drugs During Pregnancy and Lactation (Third ed.). Academic Press. pp. 687–703. doi:10.1016/B978-0-12-408078-2.00029-9.
- National Toxicology Program (2011). "NTP 12th Report on Carcinogens". Report on Carcinogens: Carcinogen Profiles. 12: iii–499. ISSN 1551-8280. PMID 21822324.
- Shalkham AS, Kirrane BM, Hoffman RS, Goldfarb DS, Nelson LS (2006). "The availability and use of charcoal hemoperfusion in the treatment of poisoned patients". American Journal of Kidney Diseases. 48 (2): 239–41. doi:10.1053/j.ajkd.2006.04.080. PMID 16860189.
- Krasinski K, Perkin R, Rutledge J (1982). "Gray baby syndrome revisited". Clinical Pediatrics. 21 (9): 571–2. doi:10.1177/000992288202100910. PMID 7105617. S2CID 31417519.
- Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, eds. (2009). "Ch.248. Antibacterial therapeutic agents". Feigin & Cherry's textbook of pediatric infectious diseases (6th ed.). Philadelphia, PA: Saunders/Elsevier. ISBN 978-1-4160-4044-6.